Poseida Therapeutics' New Treatment For Multiple Myeloma Shows Early Success In Clinical Trial
Portfolio Pulse from Vandana Singh
Poseida Therapeutics Inc (PSTX) reported positive early results from a Phase 1 study of P-BCMA-ALLO1, a CAR-T therapy candidate for multiple myeloma, in partnership with Roche Holdings AG (RHHBY). The study showed an 82% overall response rate, with high rates of partial and complete responses and well-tolerated safety profile. The news has led to a 20.6% increase in PSTX shares in premarket trading.
December 11, 2023 | 4:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Poseida Therapeutics' stock is trading higher due to positive Phase 1 results for its CAR-T therapy candidate, P-BCMA-ALLO1, showing high efficacy and safety for multiple myeloma treatment.
The positive clinical trial results are a significant milestone for Poseida Therapeutics, indicating potential for future success of P-BCMA-ALLO1. This news directly impacts investor sentiment and the perceived value of PSTX, leading to a substantial increase in its stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Roche Holdings AG, in partnership with Poseida Therapeutics, is involved in the development of P-BCMA-ALLO1, which has shown promising results in a Phase 1 study for treating multiple myeloma.
Roche's partnership with Poseida Therapeutics in developing P-BCMA-ALLO1 and the positive study results may have a favorable impact on Roche's stock, as it reflects the company's successful collaboration and investment in innovative therapies.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80